Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease

NCT01095744 | Completed

• 2 other identifiers: C08-302008-A00939-46
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The first objective is to asses influence of age on amyloid load measured by PET imaging using Pittsburgh B compound (PiB) radio-tracer, in Alzheimer's disease(AD). This will allow the determination of brains age-specific deterioration factors by comparing Early onset AD (EOAD), Late onset AD (LOAD)and atypical focal cortical AD (PCA and LPA). The amount of brain lesions in AD patients is estimated by:

1. 1.measuring the rate of cortical brain atrophy,
2. 2.FDG imaging of glucose metabolism reflecting neuronal activity, and
3. 3.for patients who benefited from a lumbar puncture; Cortical-spinal fluid (CSF) amounts of amyloïd and tau proteins are measured.

Conditions

Alzheimer's Disease; Posterior Cortical Atrophy; Logopenic Progressive Aphasia

Keywords

PIB imaging,; brain atrophy; cognitive impairment; Pet imaging; Alzheimer's disease; amyloid protein

Outcome Measures

Primary Outcomes (5)

• PIB-PET imaging of amyloid load

  PET imaging using PIB radio-tracer will give an estimation of regional amyloid load for every patient

  0 - 2 months

• FDG-PET imaging of glucose metabolism

  PET imaging using 18F-fluorodesoxyglucose (FDG) will give a visualization of regional neuronal metabolism

  0 - 2 months

• clinical phenotypic assessment

  the clinical evaluation includes a neurologic consulting, a neuropsychologic assessment of cognitive performances, and evaluation of autonomy

  0 - 2 months

• MRI

  the magnetic resonance imaging will be performed using numerous modalities like T1 weighted sequences for anatomic information, T2 weighted FLAIR and TSE sequences to avoid vascular injuries and T2 GRE to avoid microbleeds, DTI for the diffusion tensor imaging and default mode FMRI, to identify neural networks involved in default concious mode.

  0 - 2 months

• ApoE gene sequencing

  ApoE gene sequencing, will be performed after all samples have been collected. So this may be 0 to 24 month after inclusion.

  0 - 24 months after inclusion

Secondary Outcomes (1)

• amyloid and Tau measurements in cerebro-spinal fluid (csf)

  -6 months or +6months arround T0

Study Arms (5)

EOAD typical AD

this cohort is constituted with early onset typical AD.

LOAD typical

this group is constituted with late onset typical AD

atypical AD

this group is constituted with atypical form of focal cortical atrophy, like posterior cortical atrophy and logopenic progressive aphasia.

young controls

under 65

old controls

over 65

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients have to fulfil criteria for (1)AD with an amnesic syndrome of the media-temporal type, EOAD have lower frequency and (2) and for atypical Ad respecting episodic memory, inaugural language disorder or visual-spatial disorder

You may qualify if:

• AD patients: clinical dementia rating between 0.5 and 2 free and cued recall test (Grober and Buschke) cued-recall \< 18/48 and total recall \< 40/48
• atypical AD : i visual-spatial disorder and respect of episodic memory progressive evolution, Balint syndrome ii progressive language disorder constituted of logopenic aphasia respect of episodic memory
• controls: age over 30 MMSE over or equal to 27 normal neuropsychiatric state for age and education level

You may not qualify if:

• for every patients : psychiatric disorders age under18 absence of social security counter indication to MRI supposed or actual alcoholism or drug addiction pregnancy

Sponsors & Collaborators

• Institut National de la Santé Et de la Recherche Médicale, France: lead

Study Sites (1)

Pitie Salpêtrière Hospital

Paris, Île-de-France Region, 75651, France

Location

Related Publications (3)

• Dorothee G, Bottlaender M, Moukari E, de Souza LC, Maroy R, Corlier F, Colliot O, Chupin M, Lamari F, Lehericy S, Dubois B, Sarazin M, Aucouturier P. Distinct patterns of antiamyloid-beta antibodies in typical and atypical Alzheimer disease. Arch Neurol. 2012 Sep;69(9):1181-5. doi: 10.1001/archneurol.2012.604.

  PMID: 22710357 RESULT

• Migliaccio R, Agosta F, Toba MN, Samri D, Corlier F, de Souza LC, Chupin M, Sharman M, Gorno-Tempini ML, Dubois B, Filippi M, Bartolomeo P. Brain networks in posterior cortical atrophy: a single case tractography study and literature review. Cortex. 2012 Nov-Dec;48(10):1298-309. doi: 10.1016/j.cortex.2011.10.002. Epub 2011 Oct 20.

  PMID: 22099855 RESULT

• de Souza LC, Corlier F, Habert MO, Uspenskaya O, Maroy R, Lamari F, Chupin M, Lehericy S, Colliot O, Hahn-Barma V, Samri D, Dubois B, Bottlaender M, Sarazin M. Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer's disease. Brain. 2011 Jul;134(Pt 7):2036-43. doi: 10.1093/brain/awr130.

  PMID: 21705422 RESULT

Biospecimen

Retention: SAMPLES WITH DNA

DNA sample immortalized blood cell cultures csf aliquots for patients who beneficiated from a lumbar puncture.

MeSH Terms

Conditions

Alzheimer Disease; Cognitive Dysfunction; Amyloidosis

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Cognition Disorders; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Bruno Dubois, professor doctor

  INSERM U975

  PRINCIPAL INVESTIGATOR

• marie c sarzin, doctor

  Inserm U975

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 12, 2010
• First Posted: March 30, 2010
• Study Start: March 1, 2009
• Primary Completion: May 1, 2012
• Study Completion: May 1, 2012
• Last Updated: October 7, 2025

Record last verified: 2012-02

Locations

FR (1)